A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Clinical trial NCT03972709 · TERMINATED
Trial details
- NCT number
- NCT03972709
- Sponsor
- Genentech, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-06-03
- Primary completion
- 2022-10-27
- Enrollment
- 372
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.